Please login to the form below

Not currently logged in
Email:
Password:

Xalkori

This page shows the latest Xalkori news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

There were 17 patients in the Lorbrena arm and 13 in the Xalkori arm with measurable brain metastases based on baseline imaging. ... In addition, the intracranial duration of response was 12 months or longer in 79% of Lorbrena-treated patients compared

Latest news

More from news
Approximately 25 fully matching, plus 51 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    In addition Merck KGaA also gets the right to co-promote Xalkori in the US and other "key" markets.

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    of Xalkori, below - the drug can achieve accelerated approval on the basis of an interim analysis or phase II data before OS is established. ... Outcome. Xalkori(crizotinib) in NSCLC. No OS benefit shown but positive data in morbidity (symptom improvement

  • Who tops the pharma list? Who tops the pharma list?

    Pfizer's Xalkori is just one example of this.”. Alongside oncology, treatments for immunology and metabolic diseases rank among the fastest-growing therapeutic classifications.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...